Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11147770 | 1.00 | DNM1 (0.70) | DNM1ALDH1A1TSHRTP53CYP3A4 | |
| Bromide SCHEMBL8466522 | 0.95 | DNM1 (0.70) | DNM1ALDH1A1TSHRTP53CYP3A4 | |
| Bromide SCHEMBL6827078 | 0.88 | DNM1 (0.89) | DNM1ALDH1A1TSHRTP53CYP3A4 | |
| Bromide SCHEMBL5086749 | 0.88 | DNM1 (0.89) | DNM1ALDH1A1TSHRTP53CYP3A4 | |
| Bromide SCHEMBL5091560 | 0.88 | DNM1 (0.89) | DNM1ALDH1A1TSHRTP53CYP3A4 | |
| Bromide SCHEMBL5087088 | 0.88 | DNM1 (0.89) | DNM1ALDH1A1TSHRTP53CYP3A4 | |
| Bromide SCHEMBL11820808 | 0.88 | DNM1 (0.89) | DNM1ALDH1A1TSHRTP53CYP3A4 | |
| Bromide SCHEMBL5085169 | 0.88 | DNM1 (0.89) | DNM1ALDH1A1TSHRTP53CYP3A4 | |
| Bromide SCHEMBL5088585 | 0.88 | DNM1 (0.89) | DNM1ALDH1A1TSHRTP53CYP3A4 | |
| Bromide SCHEMBL2299537 | 0.88 | DNM1 (0.89) | DNM1ALDH1A1TSHRTP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | HOLMES-FARLEY STEPHEN R | 2007-08-16 | — | — | US | disclosed |
| US-7125547-B2 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-6726905-B1 | LOWERING SERUM PHOSPHATE | GENZYME CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-6610283-B1 | Method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a | GENZYME CORPORATION | 2003-08-26 | — | — | US | disclosed |
| EP-1094801-A2 | POLY(DIALLYLAMINE)-BASED BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6203785-B1 | ADMINISTERING CROSSLINKED CATIONIC POLYMER ANTICHOLESTEROL AGENTS | GELTEX PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| WO-1999022743-A1 | POLY(DIALLYLAMINE)-BASED PHOSPHATE BINDERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1998029107-A2 | POLY(DIALLYLAMINE)-BASED BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | DNM1 3581/4885ALDH1A1 2873/4885TSHR 4075/4885 |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | DNM1 3469/4885ALDH1A1 2717/4885TSHR 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.